Unlike traditional drug development, cell therapy logistics require extremely close, integrated relationships with contract research (CRO) and manufacturing (CDMO) organizations. Due to the direct line from patient to manufacturing and back, these partners function as critical extensions of the core team to ensure timeliness and safety.

Unlike small-molecule drugs, biologics manufacturing cannot be simply scaled up on demand because "the process is the product." A superior manufacturing and supply chain capability is not a back-office function but a key market differentiator that commercial teams must leverage to win customers and outpace competitors.

A capacity crunch in the US sterile fill market is driven by two factors: large pharmaceutical companies acquiring CDMO facilities for their own use, and a growing client demand for US-based manufacturing (reshoring). This creates a significant shortage and an opportunity for independent CDMOs with available capacity.

The push for supply chain diversification and reduced reliance on China is not a new phenomenon. The COVID-19 pandemic first exposed the critical risks of single-source dependency. Recent tariff threats are not the origin of this strategic realignment but rather a powerful accelerant, forcing companies to act on plans already in motion.

The CDMO market is segmenting, rewarding companies that specialize in complex niches like sterile filling. Rather than trying to do everything, focusing on being a world-class expert attracts clients who need specialized services, much like a patient chooses a heart surgeon over a general pharmacy for a critical procedure.

According to Novartis's CEO, a top reason for rejecting potential biotech partners is their underinvestment in Chemistry, Manufacturing, and Controls (CMC). Startups often neglect this unglamorous work, leading to deal failure because the acquirer can't be sure the drug can be scaled efficiently and safely.

To overcome production bottlenecks, Legend Biotech employs a diversified manufacturing strategy. They operate their own large facilities in the US and Belgium while also contracting with pharmaceutical giant Novartis to produce their CAR T therapy. This enables a rapid scale-up to a planned 10,000 annual doses.

While US tariff policies aim to bring pharmaceutical production back onshore, the immediate beneficiaries are likely to be contract manufacturers. Building new proprietary facilities is a slow and expensive process, so companies will lean on agile contract partners to quickly diversify their supply chains in the interim.

China's rise in biotech isn't just about cost. It's driven by a tightly integrated ecosystem where drug designers and wet lab technicians work closely, creating a much faster feedback loop than the siloed, outsourced model common in the US.